中文 | English
 
3月20日讲座:Texas Style Metal-based Drug Discovery Adventures

学术报告:Texas Style Metal-based Drug Discovery Adventures

报告人:Jonathan L. Sessler (教授,德州大学奥斯汀)

时间:周三(3月20日) 下午 2:30

地点:实验三楼 102室


报告内容:

This lecture will present a personal story of a 3x cancer survivor and how with the assistance of great coworkers and collaborators an effort has been made to fight back against this disease by studying the chemistry and anti-cancer biology of expanded porphyrins. Expanded porphyrin is a term we introduced into the literature in 1988 to describe larger homologues of natural blood pigments, such as the dyes (called heme) that make blood red. Many expanded porphyrins are now known. They have seen application in areas as diverse as anion recognition (capturing species with negative charges) and extraction (removal of pollutants from waste streams), photodynamic therapy (where light is used to destroy cancer), and aromaticity (a fundamental property of organic chemistry).

  

In this presentation, the focus will be on a set of expanded porphyrins called texaphyrins. These compounds were named for the State of Texas due to their size. Two of the texaphyrin complexes, known as MGd and MLu, were the founding technology for Pharmacyclics, Inc., a company that later developed a best-selling leukemia drug and was acquired by AbbVie for $21B in 2015. New work involving the creation of a possible drug lead, oxaliTEX-Pt(IV), targeting platinum-resistant ovarian cancer, will then be described. Explorations of gold-based carbenes as triggers of immunogenic cell death and possible cancer vaccines will also be presented.

  

报告人简介:

Prof. Jonathan L. Sessler is the Doherty-Welch Chair in Chemistry at the College of Natural Sciences, at the University of Texas at Austin. He has authored or coauthored over 730 research publications, written two books, edited two others, and been an inventor of record on over 75 issued U.S. Patents. To date, Dr. Sessler’s work has been featured on more than 50 journal or book covers. His current H-index is 101. Dr. Sessler is an Associate Editor for ChemComm. He struggles with Korean. Dr. Sessler’s work has been recognized with several awards, including the ACS Cope Scholar Award, the RSC Centenary Prize, the Southwest Regional ACS Award, the Molecular Sensors-Molecular Logic Gates Award, the CASE award, and the Hans Fischer Award. He is a member of the U.S. National Academy of Inventors and was named Inventor of the Year at The Univ. of Texas at Austin in 2016. Dr. Sessler recently received the 2018 Thomas Dougherty Award in Photodynamic Therapy from the Society of Porphyrins and Phthalocyanines. In 2019, he will receive the C. David Gutsche Award in Calixarene Chemistry. Dr. Sessler was just elected to the European Academy of Sciences (class of 2019).

  

网页发布时间: 2019-03-19 15:47